# A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment

> **NCT06400511** · PHASE3 · TERMINATED · sponsor: **Famy Life Sciences, a Viatris Company** · enrollment: 477 (actual)

## Conditions studied

- Blepharitis

## Interventions

- **DRUG:** Pimecrolimus 0.3% Ophthalmic Ointment
- **DRUG:** Placebo Ophthalmic Ointment

## Key facts

- **NCT ID:** NCT06400511
- **Lead sponsor:** Famy Life Sciences, a Viatris Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-04-22
- **Primary completion:** 2025-09-09
- **Final completion:** 2025-10-15
- **Target enrollment:** 477 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06400511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06400511, "A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06400511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*